239 related articles for article (PubMed ID: 3012508)
21. The pharmacology of aldose reductase inhibitors.
Kador PF; Robison WG; Kinoshita JH
Annu Rev Pharmacol Toxicol; 1985; 25():691-714. PubMed ID: 3923907
[No Abstract] [Full Text] [Related]
22. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
Cameron NE; Cotter MA; Basso M; Hohman TC
Diabetologia; 1997 Mar; 40(3):271-81. PubMed ID: 9084964
[TBL] [Abstract][Full Text] [Related]
23. Does aldose reductase have a role in the development of the ocular complications of diabetes?
Lightman S
Eye (Lond); 1993; 7 ( Pt 2)():238-41. PubMed ID: 7607342
[TBL] [Abstract][Full Text] [Related]
24. Biochemical and vascular factors in the pathogenesis of diabetic neuropathy.
Ward JD
Clin Invest Med; 1995 Aug; 18(4):267-74. PubMed ID: 8549012
[TBL] [Abstract][Full Text] [Related]
25. [Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications].
Hotta N; Sakamoto N
Nihon Rinsho; 1987 Dec; 45(12):3010-27. PubMed ID: 3128677
[No Abstract] [Full Text] [Related]
26. New therapies for the chronic complications of older diabetic patients.
Clements RS
Am J Med; 1986 May; 80(5A):54-60. PubMed ID: 3085495
[TBL] [Abstract][Full Text] [Related]
27. Aldose reductase inhibitors and the complications of diabetes mellitus.
Tomlinson DR
Diabet Med; 1993 Apr; 10(3):214-30. PubMed ID: 8485953
[No Abstract] [Full Text] [Related]
28. Aldose reductase, ocular diabetic complications and the development of topical Kinostat(®).
Kador PF; Wyman M; Oates PJ
Prog Retin Eye Res; 2016 Sep; 54():1-29. PubMed ID: 27102270
[TBL] [Abstract][Full Text] [Related]
29. Polyol pathway in the pathogenesis of diabetic complications and aldose reductase inhibitors.
Madhu SV; Verma NP; Goel A; Kapoor VK
J Assoc Physicians India; 1992 Oct; 40(10):679-81. PubMed ID: 1307356
[No Abstract] [Full Text] [Related]
30. An aldose reductase inhibitor, TAT, reduces ADP-induced platelet hyperaggregation in streptozotocin-induced diabetic rats with neuropathy.
Hara T; Nakamura J; Koh N; Sakakibara F; Hamada Y; Sasaki H; Naruse K; Nakashima E; Takeuchi N; Inukai S
J Lab Clin Med; 1995 Dec; 126(6):541-7. PubMed ID: 7490513
[TBL] [Abstract][Full Text] [Related]
31. Aldose reductase inhibitors and their potential for the treatment of diabetic complications.
Tomlinson DR; Stevens EJ; Diemel LT
Trends Pharmacol Sci; 1994 Aug; 15(8):293-7. PubMed ID: 7940997
[TBL] [Abstract][Full Text] [Related]
32. The identification of aldose reductase in the pathogenesis of diabetic complications: the background.
Kador PF; Kinoshita JH
Diabet Med; 1985 May; 2(3):187-9. PubMed ID: 2952417
[No Abstract] [Full Text] [Related]
33. [Effects of transgenic human aldose reductase and sorbitol dehydrogenase deficiency on diabetes complications].
Ii S; Itakura M
Nihon Rinsho; 2002 Aug; 60 Suppl 8():85-90. PubMed ID: 12355842
[No Abstract] [Full Text] [Related]
34. Genetic analysis of aldose reductase in diabetic complications.
Chung SS; Chung SK
Curr Med Chem; 2003 Aug; 10(15):1375-87. PubMed ID: 12871135
[TBL] [Abstract][Full Text] [Related]
35. [Degenerative diabetic complications. Is persistent hyperglycemia more dangerous than wide glycemic fluctuations? (author's transl)].
Pirart J
Nouv Presse Med; 1978 Dec; 7(44):4031-5. PubMed ID: 733571
[TBL] [Abstract][Full Text] [Related]
36. Polyol formation and NADPH-dependent reductases in dog retinal capillary pericytes and endothelial cells.
Sato S; Secchi EF; Lizak MJ; Fukase S; Ohta N; Murata M; Tsai JY; Kador PF
Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):697-704. PubMed ID: 10067973
[TBL] [Abstract][Full Text] [Related]
37. Metabolic abnormalities contributing to diabetic complications. II. Peripheral nerves.
Anderson JW
Am J Clin Nutr; 1976 Apr; 29(4):402-8. PubMed ID: 178166
[No Abstract] [Full Text] [Related]
38. Aldose reductase in the etiology of diabetic complications. 3. Neuropathy.
Stribling D; Armstrong FM; Perkins CM; Smith JC
J Diabet Complications; 1989; 3(3):139-48. PubMed ID: 2528557
[TBL] [Abstract][Full Text] [Related]
39. The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient.
Lorenzi M
Exp Diabetes Res; 2007; 2007():61038. PubMed ID: 18224243
[TBL] [Abstract][Full Text] [Related]
40. Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats.
Cotter MA; Cameron NE; Hohman TC
J Peripher Nerv Syst; 1998; 3(3):217-23. PubMed ID: 10959252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
